Document is current
Any future updates will be listed below
-
Authors
Kempynck, Niklas https://orcid.org/0000-0002-0104-4844
De Winter, Seppe https://orcid.org/0000-0001-7907-1247
Blaauw, Casper H. https://orcid.org/0000-0001-8145-9726
Konstantakos, Vasileios https://orcid.org/0000-0002-0332-7506
Ekşi, Eren Can https://orcid.org/0000-0002-3122-9858
Dieltiens, Sam https://orcid.org/0000-0003-1165-2189
Abaffyová, Darina https://orcid.org/0000-0002-0636-517X
Bercier, Valérie https://orcid.org/0000-0002-2672-7705
Taskiran, Ibrahim I. https://orcid.org/0000-0002-5077-5264
Hulselmans, Gert
Spanier, Katina https://orcid.org/0000-0002-1375-4157
Christiaens, Valerie
Van Den Bosch, Ludo https://orcid.org/0000-0003-0104-4067
Mahieu, Lukas https://orcid.org/0009-0002-5085-6985
Aerts, Stein https://orcid.org/0000-0002-8006-0315
- License Information
-
More Information
Article History
Received: 2 April 2025
Accepted: 4 March 2026
First Online: 2 April 2026
Competing interests
: L.V.D.B. is head of the Scientific Advisory Board of Augustine Therapeutics (Leuven, Belgium) and is part of the Investment Advisory Board of Droia Ventures (Meise, Belgium). I.I.T. is currently associated with Illumina. The other authors declare no competing interests.
